TechBio company Cytomos has appointed Dr. Fernanda Masri as Chief Commercial and Innovation Officer and Dr. Christel Fenge as Techno-Commercial Adviser.
 
In her new role, Masri will spearhead Cytomos’ commercialization strategy, as the company rapidly evolves the technology into a commercial product platform suitable from early R&D and Product Development through to manufacturing, building on the progress over the past decade. 
 
Meanwhile, Fenge will provide valuable input into both market potential and market penetration analysis and the company’s ‘go to market’ strategy.
 
CEO, David Rigterink, commented: “We are delighted that Fernanda and Christel have joined the Cytomos team at this important juncture in the company’s development. Indeed, their commercial skills and expertise will be pivotal to the next phase in Cytomos’ development. Fernanda will spearhead the company’s commercialization plans and our ‘go to market’ strategy and Christel will play a central role within it.”

About Dr. Fernanda Masri

Masri served as Head of Innovation Manufacturing and Collaborations at Cell and Gene Therapy Catapult. She also worked at Sartorius as a Technology Expert for Regenerative Medicine where she helped to accelerate development and manufacture of cell and gene therapies, making them more readily accessible to patients across the globe.
 
Moreover, as a solutions manager for iPSCs, Masri was responsible for developing and implementing a global portfolio of tools and services, specifically geared to iPSC customers. Prior to this, she developed her process engineering skills at the Centre for Commercialization of Regenerative Medicine (CCRM) in Canada.

About Dr. Christel Fenge

Fenge previously served as Vice President, R&D Bioprocess at Cytiva with responsibility for upstream and downstream product development and Vice President, Marketing and Product Management Fermentation Technologies at Sartorius.
 
She served as General Manager of Recipharm Biologics, a mid-sized CMO, and held senior management positions in biopharmaceutical development at AstraZeneca. She began her industrial career in cell culture process development at Pharmacia & Upjohn and was involved in the development of RefactoÔ.